Darya Chudova Sells 5,451 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CTO Darya Chudova sold 5,451 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $104.04, for a total transaction of $567,122.04. Following the sale, the chief technology officer directly owned 7,012 shares in the company, valued at approximately $729,528.48. The trade was a 43.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Darya Chudova also recently made the following trade(s):

• On Monday, December 8th, Darya Chudova sold 13,664 shares of Guardant Health stock. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56.
• On Monday, December 8th, Darya Chudova sold 9,271 shares of Guardant Health stock. The shares were sold at an average price of $106.00, for a total transaction of $982,726.00.

Guardant Health Stock Performance

Guardant Health stock opened at $97.10 on Friday. The company’s 50 day simple moving average is $91.51 and its 200-day simple moving average is $67.00. Guardant Health, Inc. has a 1 year low of $29.91 and a 1 year high of $112.43. The company has a market capitalization of $12.24 billion, a price-to-earnings ratio of -30.25 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.88) EPS. Equities analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GH has been the topic of several research reports. JPMorgan Chase & Co. increased their target price on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a research note on Thursday, September 25th. William Blair reissued an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Citigroup lifted their price objective on shares of Guardant Health from $100.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, UBS Group increased their target price on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $95.52.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Signaturefd LLC grew its stake in Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after buying an additional 213 shares during the last quarter. IFP Advisors Inc lifted its stake in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after acquiring an additional 552 shares during the period. Sound Income Strategies LLC purchased a new position in shares of Guardant Health during the third quarter worth approximately $38,000. Finally, Optiver Holding B.V. increased its holdings in shares of Guardant Health by 153.5% in the 3rd quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock valued at $48,000 after acquiring an additional 465 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.